We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current TRML market cap is 449.77M. The company's latest EPS is USD -1.6427 and P/E is -10.67.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.97M | -3.42M | -17.52M | -21.97M | -24.44M |
| Net Income | -7.02M | 2.13M | -13.31M | -17.49M | -20.18M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.38M | -22.68M | -47.51M | -76.48M | -45.41M |
| Net Income | -18.16M | -22.71M | -47.83M | -73.89M | -42.12M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 151.06M | 210.3M | 359.17M | 344.79M | 328.45M |
| Total Liabilities | 8.19M | 5.25M | 5.03M | 6.51M | 7.38M |
| Total Equity | 142.87M | 205.04M | 354.14M | 338.28M | 321.07M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 41.94M | 152.78M | 251.42M | 193.72M | 210.3M |
| Total Liabilities | 2.35M | 4.77M | 8.61M | 13.66M | 5.25M |
| Total Equity | -17.1M | -38.15M | 242.81M | 180.06M | 205.04M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -39.1M | -28.08M | -14.92M | -32.93M | -56.37M |
| Investing | 92.26M | 3.84M | -188.87M | -199M | -210.7M |
| Financing | 257k | 156.72M | 161.35M | 161.35M | 161.35M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.66M | -19.21M | -39.99M | -60.86M | -28.08M |
| Investing | -562k | -133.3M | -96.39M | 55.67M | 3.84M |
| Financing | 36.2M | 131.12M | 137.4M | 242k | 156.72M |
| Market Cap | 449.77M |
| Price to Earnings Ratio | -10.67 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.19 |
| Price to Book Ratio | 2.19 |
| Dividend Yield | - |
| Shares Outstanding | 25.64M |
| Average Volume (1 week) | 222.22k |
| Average Volume (1 Month) | 197.86k |
| 52 Week Change | -55.37% |
| 52 Week High | 48.31 |
| 52 Week Low | 12.12 |
| Spread (Intraday) | 1.71 (9.51%) |
| Company Name | Tourmaline Bio Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://talaristx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
